Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
six
months ended in Dec. 2025,
Genertec Universal Medical Group Co paid€0 Mil more to buy back shares than it received from issuing new shares.
It spent€216 Mil paying down its debt.
It paid€0 Mil more to buy back preferred shares than it received from issuing preferred shares.
It spent€1 Mil paying cash dividends to shareholders.
It spent€40 Mil on other financial activities.
In all, Genertec Universal Medical Group Cospent€258 Mil on financial activities for the
six
months ended in Dec. 2025.
Genertec Universal Medical Group Co (FRA:5UM) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
Genertec Universal Medical Group Co's issuance of stock for the
six
months ended in Dec. 2025 was €0 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
Genertec Universal Medical Group Co's repurchase of stock for the
six
months ended in Dec. 2025 was €0 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
Genertec Universal Medical Group Co's net issuance of debt for the
six
months ended in Dec. 2025 was €-216 Mil.
Genertec Universal Medical Group Co spent€216 Mil paying down its debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
Genertec Universal Medical Group Co's net issuance of preferred for the
six
months ended in Dec. 2025 was €0 Mil.
Genertec Universal Medical Group Co paid€0 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Genertec Universal Medical Group Co's cash flow for dividends for the
six
months ended in Dec. 2025 was €-1 Mil.
Genertec Universal Medical Group Co spent€1 Mil paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
Genertec Universal Medical Group Co's other financing for the
six
months ended in Dec. 2025 was €-40 Mil.
Genertec Universal Medical Group Co spent€40 Mil on other financial activities.
Genertec Universal Medical Group Co Cash Flow from Financing Related Terms
Genertec Universal Medical Group Co Cash Flow from Financing Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genertec Universal Medical Group Co Cash Flow from Financing Chart
Genertec Universal Medical Group Co Cash Flow from Financing Calculation
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-617 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Financing of €-617 Mil mean?
Genertec Universal Medical Group Co (FRA:5UM) has a Cash Flow from Financing of €-617 Mil as of Dec. 2025. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Genertec Universal Medical Group Co and its competitors.
Is Genertec Universal Medical Group Co's Cash Flow from Financing too high?
Genertec Universal Medical Group Co's current Cash Flow from Financing is €-617 Mil. Overall, Genertec Universal Medical Group Co has a GF Score™ of 48/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Genertec Universal Medical Group Co's Cash Flow from Financing compare to V and MA?
Genertec Universal Medical Group Co's Cash Flow from Financing of €-617 Mil can be compared against companies in the Credit Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Credit Services company?
A good Cash Flow from Financing depends on the Credit Services industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Genertec Universal Medical Group Co and its competitors. Genertec Universal Medical Group Co's current Cash Flow from Financing is €-617 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genertec Universal Medical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Genertec Universal Medical Group Co (FRA:5UM) is currently considered Fairly Valued. The stock's GF Value™ is €0.46, compared to a current price of €0.50 — trading 8.3% above its estimated fair value. The current Cash Flow from Financing is €-617 Mil. Genertec Universal Medical Group Co's overall GF Score™ is 48/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For Genertec Universal Medical Group Co (FRA:5UM), the current Cash Flow from Financing is €-617 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genertec Universal Medical Group Co (FRA:5UM) Overvalued in 2026?
Based on GuruFocus' analysis, Genertec Universal Medical Group Co stock appears to be overvalued.
The current stock price of €0.50 is trading 8.3% above its estimated GF Value™ of €0.46.
GuruFocus considers Genertec Universal Medical Group Co to be Fairly Valued.
Key valuation signals for FRA:5UM:
Cash Flow from Financing: €-617 Mil
GF Value™: €0.46 vs. price of €0.50 (8.3% above fair value)
No single metric tells the full story. See the FRA:5UM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genertec Universal Medical Group Co Ltd is principally engaged in providing financing to its customers under finance lease arrangements, the provision of advisory services, the sale of medical equipment as well as leases under operating lease arrangements, and the provision of other services. The group has two business segments namely The finance business comprises direct finance leasing, sale-and-leaseback, factoring, operating leases, and advisory services; and Healthcare business comprises includes hospital group business, healthcare technology business and specialty business. Geographically, it derives a majority of its revenue from Mainland China.
48GF Score
Get the complete analysis for FRA:5UM
Cash Flow from Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5UM has been successfully added to your 
